XEN Glaucoma Implant for the Management of Operated Uncontrolled Glaucoma: Results and Complications during a Long-Term Follow-Up

This study aimed to analyze the surgical and refractive outcomes of XEN glaucoma implant (Allergan, an Abbvie company, Irvine, CA, USA), a minimally invasive surgical device for the treatment of operated uncontrolled glaucoma. Eyes that received XEN Gel Stent placement from December 2014 to October...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:J Ophthalmol
Autors principals: Lewczuk, Katarzyna, Konopińska, Joanna, Jabłońska, Joanna, Rudowicz, Jacek, Laszewicz, Patrycja, Mariak, Zofia, Rękas, Marek
Format: Artigo
Idioma:Inglês
Publicat: Hindawi 2021
Matèries:
Research Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC8285170/
https://ncbi.nlm.nih.gov/pubmed/34306742
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1155/2021/2321922
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars